VistaGen Therapeutics(VTGN) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing with ongoing PALISADE-3, PALISADE-4 and Repeat Dose trials Vistagen highlights clinical-stage pipeline with five novel pherine product candidates with positive ef icacy signals and potential to transform standards of care for multiple high prevalence indications SOUTH SAN FRANCISCO, Calif. ...